共 188 条
[1]
Liedtke C(2008)Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 1275-81
[2]
Mazouni C(2011)Triple-negative breast cancer: an unmet medical need Oncologist 16 1-11
[3]
Hess KR(2007)Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry Cancer 109 1721-8
[4]
Andre F(2007)Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429-34
[5]
Tordai A(2013)Updates in the treatment of basal/triple-negative breast cancer Curr Opin Obstet Gynecol 25 40-8
[6]
Mejia JA(2008)Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases Cancer 113 2638-45
[7]
Hudis CA(2005)Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 5678-85
[8]
Gianni L(2014)Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer J Clin Oncol 32 3840-7
[9]
Bauer KR(2014)Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol 32 3307-29
[10]
Brown M(2014)ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) Ann Oncol 25 1871-88